LIANY
LianBio
Key Financials
Operating Income
$-125353000
↑ 35.9%
Net Income
$-110290000
↑ 43.8%
Total Assets
$320.0M
↓ 25.0%
Total Liabilities
$26.3M
↓ 32.5%
EPS (Diluted)
$-1.02
↑ 82.1%
Cash & Equivalents
$79.2M
↓ 65.3%
Shareholders' Equity
$259.9M
↓ 26.5%
Operating Cash Flow
$-99185000.00
↑ 39.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SC 13G | 11/14/2024 | View on SEC |
| 4 | 4/11/2024 | View on SEC |
| 15-12G | 3/21/2024 | View on SEC |
| EFFECT | 3/12/2024 | View on SEC |
| F-6 POS | 3/12/2024 | View on SEC |
| S-8 POS | 3/12/2024 | View on SEC |
| S-8 POS | 3/12/2024 | View on SEC |
| S-8 POS | 3/12/2024 | View on SEC |
| POS AM | 3/12/2024 | View on SEC |
| 25 | 3/11/2024 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | LIANY |
| Company Name | LianBio |
| CIK | 1831283 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | E9 |
| Phone | (609) 486-2308 |